TY - JOUR
T1 - Weight and Body Composition Changes during and after Adjuvant Chemotherapy in Women with Breast Cancer
AU - Freedman, Renee J.
AU - Aziz, N.
AU - Albanes, D.
AU - Hartman, T.
AU - Danforth, D.
AU - Hill, S.
AU - Sebring, N.
AU - Reynolds, J. C.
AU - Yanovski, J. A.
PY - 2004/5
Y1 - 2004/5
N2 - Uncontrolled trials have reported significant weight gain in women with breast cancer during treatment with adjuvant chemotherapy. We prospectively evaluated body composition before (visit 1), immediately after (visit 2), and 6 months after (visit 3) chemotherapy in 20 women with stages I-IIIA breast cancer [body mass index (BMI): 24.1 ± 3.9 kg/m2]. We compared their weight change to 51 age- and BMI-matched healthy controls (BMI: 25.5 ± 3.8 kg/m2). In women with breast cancer, there was no weight change from visit 1-2, or from visit 1-3, but weight increased from visit 2-3 (+1.09 ± 2.46 kg; P = 0.05). Weight change was not different from controls during either interval. In the breast cancer group, the percentage of body fat assessed by air displacement plethysmography increased, and fat-free mass decreased from visit 1-2 (+2.3 ± 4% and -2.2 ± 4%; P = 0.02) and from visit 1-3 (+4.0 ± 6% and -3.8 ± 6%; P = 0.01). By dual energy x-ray absorptiometry, the percentage of body fat increased from visit 2-3 (+0.9 ± 1.6%; P = 0.02). Bone mineral content decreased from visit 2-3 (-0.02 ± 0.04 kg; P = 0.02) and from visit 1-3 (-0.04 ± 0.06 kg;, P = 0.005). By computed tomography, the visceral adipose to sc adipose tissue ratio decreased from visit 1-3 (-0.02 ± 0. 05 ml; P = 0.02). We conclude that, compared with controls, women with breast cancer receiving modern adjuvant chemotherapy regimens show no significant changes in weight during the first year of their treatment. They do, however, appear to undergo unfavorable changes in body composition.
AB - Uncontrolled trials have reported significant weight gain in women with breast cancer during treatment with adjuvant chemotherapy. We prospectively evaluated body composition before (visit 1), immediately after (visit 2), and 6 months after (visit 3) chemotherapy in 20 women with stages I-IIIA breast cancer [body mass index (BMI): 24.1 ± 3.9 kg/m2]. We compared their weight change to 51 age- and BMI-matched healthy controls (BMI: 25.5 ± 3.8 kg/m2). In women with breast cancer, there was no weight change from visit 1-2, or from visit 1-3, but weight increased from visit 2-3 (+1.09 ± 2.46 kg; P = 0.05). Weight change was not different from controls during either interval. In the breast cancer group, the percentage of body fat assessed by air displacement plethysmography increased, and fat-free mass decreased from visit 1-2 (+2.3 ± 4% and -2.2 ± 4%; P = 0.02) and from visit 1-3 (+4.0 ± 6% and -3.8 ± 6%; P = 0.01). By dual energy x-ray absorptiometry, the percentage of body fat increased from visit 2-3 (+0.9 ± 1.6%; P = 0.02). Bone mineral content decreased from visit 2-3 (-0.02 ± 0.04 kg; P = 0.02) and from visit 1-3 (-0.04 ± 0.06 kg;, P = 0.005). By computed tomography, the visceral adipose to sc adipose tissue ratio decreased from visit 1-3 (-0.02 ± 0. 05 ml; P = 0.02). We conclude that, compared with controls, women with breast cancer receiving modern adjuvant chemotherapy regimens show no significant changes in weight during the first year of their treatment. They do, however, appear to undergo unfavorable changes in body composition.
UR - http://www.scopus.com/inward/record.url?scp=2442436518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442436518&partnerID=8YFLogxK
U2 - 10.1210/jc.2003-031874
DO - 10.1210/jc.2003-031874
M3 - Article
C2 - 15126549
AN - SCOPUS:2442436518
SN - 0021-972X
VL - 89
SP - 2248
EP - 2253
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 5
ER -